Our CEO, Andrew Satz, recently spoked at “Alumni in Conversation,” hosted by Columbia University School of General Studies. During the discussion, Andrew explained how EVQLV’s algorithm models the drug discovery process.
Brett Averso (CTO, EVQLV) and Bhoomika Kumar (SciTech intern, EVQLV) teamed up to provide a high-level overview of how EVQLV’s evolutionary algorithm works.
Andrew Satz, CEO of EVQLV, explains how our technology works, with specific attention to our progress on COVID-19.
EVQLV uses artificial intelligence (AI) to discover and optimize novel biologics. Our algorithm uses an evolutionary approach with applied external pressures to generate candidates. There’s a lot more to it, but we thought you might enjoy a taste of our “secret sauce.”